Communiqués 4D Molecular Therapeutics, Inc.

Actions

FDMT

US35104E1001

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 17:02:18 05/10/2026			Varia. 5j.	Varia. 1 janv.
12,94 ^USD	-5,34%		-11,68%	+71,47%

28/09	4D Molecular Therapeutics fait passer 4D-150 en phase 3 dans l’œdème maculaire diabétique avec le lancement de 4SIGHT	CI
28/09	4D Molecular Therapeutics lance une étude de phase 3 de 4D-150 dans l’œdème maculaire diabétique	MT

Communiqués

14:00	4DMT to Host Investor Day on October 21, 2026	GL
28/09	4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME	GL
11/09	4DMT Announces New Employment Inducement Grants	GL
25/08	4DMT to Participate in Upcoming Investor Conferences	GL
25/08	4DMT to Participate in Upcoming Investor Conferences	AQ
14/08	4DMT Announces New Employment Inducement Grants	GL
13/08	4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones	GL
20/07	4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population	AQ
18/07	4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population	GL
17/07	4DMT Announces New Employment Inducement Grants	GL
30/06	4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists	GL
29/06	4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD	GL
29/06	4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD	AQ
29/06	4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital	GL
12/06	4DMT Announces New Employment Inducement Grants	GL
27/05	4DMT to Participate in Upcoming Investor Conferences	GL
18/05	4DMT Announces New Employment Inducement Grants	AQ
15/05	4DMT Announces New Employment Inducement Grants	GL
08/05	4D Molecular Therapeutics : 4DMT Corporate Presentation – May 2026 (b30118)	PU
08/05	4D Molecular Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones	GL
04/05	4DMT to Participate in Upcoming Investor Conferences	GL
04/05	4DMT to Participate in Upcoming Investor Conferences	AQ
17/04	4DMT Announces New Employment Inducement Grants	GL
18/03	4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5)	PU